BACKGROUND: Influenza vaccine production capacity is still insufficient to meet global demand in case of a pandemic. To expand worldwide influenza vaccine production capacity, a solid and transferable egg-based influenza vaccine production process was established that is suitable for upscaling and technology transfer to vaccine manufacturers in low- and middle-income countries. As a proof-of-concept, the safety and immunogenicity of a pandemic whole inactivated virus (WIV) vaccine (H5N1) and a monovalent seasonal WIV vaccine (H3N2) were evaluated in a phase I clinical trial in adults. METHODS: Subjects were vaccinated with 2 doses of pandemic WIV vaccine (pWIV), or one dose of either seasonal WIV vaccine (sWIV) or a commercially available trivalent comparator vaccine followed by a placebo dose. Haemagglutination inhibiting antibody titres against the influenza strains were determined before and 21 d after each vaccination. RESULTS: The frequency and severity of adverse reactions were comparable between groups. No serious adverse events were reported. After a single dose of sWIV the seroconversion rate was 91% (Committee for Proprietary Medicinal Products (CPMP) criterion >40%), the seroprotection rate was 100% (CPMP criterion >70%), and the mean geometricmean titre (GMT) increase was 24.9 (CPMP criterion >2.5). After two doses of pWIV, seroconversion rate and seroprotection rate were both 71%, and the mean GMT increase was 7.8. CONCLUSIONS: Both pWIV and sWIV were equally well-tolerated as the comparator vaccine, and both vaccines complied with all 3 CPMP criteria. EudraCT 2011-000159-17. Netherlands National Trial Register 2695.
RCT Entities:
BACKGROUND: Influenza vaccine production capacity is still insufficient to meet global demand in case of a pandemic. To expand worldwide influenza vaccine production capacity, a solid and transferable egg-based influenza vaccine production process was established that is suitable for upscaling and technology transfer to vaccine manufacturers in low- and middle-income countries. As a proof-of-concept, the safety and immunogenicity of a pandemic whole inactivated virus (WIV) vaccine (H5N1) and a monovalent seasonal WIV vaccine (H3N2) were evaluated in a phase I clinical trial in adults. METHODS: Subjects were vaccinated with 2 doses of pandemic WIV vaccine (pWIV), or one dose of either seasonal WIV vaccine (sWIV) or a commercially available trivalent comparator vaccine followed by a placebo dose. Haemagglutination inhibiting antibody titres against the influenza strains were determined before and 21 d after each vaccination. RESULTS: The frequency and severity of adverse reactions were comparable between groups. No serious adverse events were reported. After a single dose of sWIV the seroconversion rate was 91% (Committee for Proprietary Medicinal Products (CPMP) criterion >40%), the seroprotection rate was 100% (CPMP criterion >70%), and the mean geometric mean titre (GMT) increase was 24.9 (CPMP criterion >2.5). After two doses of pWIV, seroconversion rate and seroprotection rate were both 71%, and the mean GMT increase was 7.8. CONCLUSIONS: Both pWIV and sWIV were equally well-tolerated as the comparator vaccine, and both vaccines complied with all 3 CPMP criteria. EudraCT 2011-000159-17. Netherlands National Trial Register 2695.
Authors: Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Abylay R Sansyzbay; Marianna K Erofeeva; Berik M Khairullin; Nurlan T Sandybayev; Zhailaubay K Kydyrbayev; Seidigapbar M Mamadaliyev; Markhabat M Kassenov; Maria V Sergeeva; Julia R Romanova; Vera Z Krivitskaya; Oleg I Kiselev; Marina A Stukova Journal: Clin Vaccine Immunol Date: 2013-06-26
Authors: Iain Stephenson; Karl G Nicholson; Reinhardt Glück; Robert Mischler; Robert W Newman; Abraham M Palache; Neville Q Verlander; Fiona Warburton; John M Wood; Maria C Zambon Journal: Lancet Date: 2003-12-13 Impact factor: 79.321
Authors: Felix Geeraedts; Nadege Goutagny; Veit Hornung; Martina Severa; Aalzen de Haan; Judith Pool; Jan Wilschut; Katherine A Fitzgerald; Anke Huckriede Journal: PLoS Pathog Date: 2008-08-29 Impact factor: 6.823
Authors: Brendon Y Chua; Toshiki Sekiya; Marios Koutsakos; Naoki Nomura; Louise C Rowntree; Thi H O Nguyen; Hayley A McQuilten; Marumi Ohno; Yuki Ohara; Tomohiro Nishimura; Masafumi Endo; Yasushi Itoh; Jennifer R Habel; Kevin J Selva; Adam K Wheatley; Bruce D Wines; P Mark Hogarth; Stephen J Kent; Amy W Chung; David C Jackson; Lorena E Brown; Masashi Shingai; Katherine Kedzierska; Hiroshi Kida Journal: PLoS Pathog Date: 2022-10-07 Impact factor: 7.464